Skip to Main Content

Table 4. Frequency of Coronary Bypass Graft Surgery in Trials of Glycoprotein IIb/IIIa Antagonists

* Total coronary arterial bypass graft surgery at 30 days.

EPIC = Evaluation of GPIIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications; EILOG = Evaluation in PTCA to Improve Long-term Outcome with Abciximab GPIIb/IIIa Blockade; CAPTURE = Chimeric Antiplatelet Therapy in Unstable Angina Refractory to Standard Medical Therapy; EPISTENT = Evaluation of Platelet Inhibitor for Stenting; IMPACT-II = Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II; PURSUIT = Platelet GPIIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy; RESTORE = Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis; PRISM = Platelet Receptor Inhibition in Ischemic Syndrome Management; PRISM-PLUS = Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms; PARAGON-A = Platelet GPIIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network; heparin (std) = initial bolus of 100 U/kg heparin before interventional procedure, with additional weight-adjusted boluses to achieve and maintain an activated clotting time greater than 300 s.

Table 4. Frequency of Coronary Bypass Graft Surgery in Trials of Glycoprotein IIb/IIIa Antagonists
Table 4. Frequency of Coronary Bypass Graft Surgery in Trials of Glycoprotein IIb/IIIa Antagonists
Close Modal

or Create an Account

Close Modal
Close Modal